Growth Hormone Deficiency Market Trends

  • Report ID: 2683
  • Published Date: Oct 16, 2024
  • Report Format: PDF, PPT

Growth Hormone Deficiency Market Trends

Growth Drivers

  • Increase in the prevalence of serious chronic diseases

Chronic diseases such as growth retardation, pituitary dysfunctions, accompanied by changing lifestyle, the prevalence of other genetic disorders, incidence of GHD in adults, and surge in compliance for growth hormone creations are the key factors that are driving the growth of the global market.

Furthermore, initiatives taken by numerous government and private organizations to spread alertness about growth hormone deficiencies,  rise in disposable income, a surge in healthcare facilities in developing nations, and awareness for human growth hormone treatment are estimated to drive the market growth during the forecast period.

Challenges

  • Unfavorable effects of growth hormones on the human body

Side effects of growth hormones such as muscle pain, joint pain, and fluid retention might surface are the growth hindrances for the market.Furthermore, stringent government regulations and high cost involved in the treatments using these growth hormones might also contribute as growth constraints for the overall market.

 

Growth Hormone Deficiency Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

3.7%

Base Year Market Size (2023)

USD 4.51 billion

Forecast Year Market Size (2036)

USD 7.23 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
 
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2683
  • Published Date: Oct 16, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of growth hormone deficiency is assessed at USD 4.64 billion.

Growth Hormone Deficiency Market size was valued at USD 4.51 billion in 2023 and is expected to reach USD 7.23 billion by 2036, registering around 3.7% CAGR during the forecast period i.e., between 2024-2036.

North America industry is expected to hold largest revenue share by 2036, attributed to factors such as high healthcare expenditure, and amplified intake of human growth hormone therapies in the region in order to cure different syndromes such as Turner syndrome.

The major players in the market are Merck KGaA, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, Ferring B.V., Novo Nordisk A/S, Eli Lilly and Company, AnkeBio Co., Ltd, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample